AR091478A1 - Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa) - Google Patents
Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)Info
- Publication number
- AR091478A1 AR091478A1 ARP130102143A AR091478A1 AR 091478 A1 AR091478 A1 AR 091478A1 AR P130102143 A ARP130102143 A AR P130102143A AR 091478 A1 AR091478 A1 AR 091478A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- receptor
- glucagon analog
- glucagon
- optionally
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 8
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 title 2
- 230000000694 effects Effects 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 10
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 abstract 1
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 abstract 1
- 101000985642 Homo sapiens Metallothionein-3 Proteins 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662874P | 2012-06-21 | 2012-06-21 | |
| US201361787973P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091478A1 true AR091478A1 (es) | 2015-02-04 |
Family
ID=48692696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102143 AR091478A1 (es) | 2012-06-21 | 2013-06-18 | Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa) |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9868772B2 (https=) |
| EP (1) | EP2864350B1 (https=) |
| JP (1) | JP6300239B2 (https=) |
| KR (1) | KR20150039748A (https=) |
| CN (1) | CN104583233B (https=) |
| AR (1) | AR091478A1 (https=) |
| AU (1) | AU2013277372B2 (https=) |
| BR (1) | BR112014031671A2 (https=) |
| CA (1) | CA2877127A1 (https=) |
| CL (1) | CL2014003421A1 (https=) |
| CO (1) | CO7170125A2 (https=) |
| CR (1) | CR20150015A (https=) |
| DK (1) | DK2864350T3 (https=) |
| EA (1) | EA029025B1 (https=) |
| ES (1) | ES2674946T3 (https=) |
| HR (1) | HRP20180936T1 (https=) |
| HU (1) | HUE039267T2 (https=) |
| IL (1) | IL236386B (https=) |
| MX (1) | MX356000B (https=) |
| MY (1) | MY185217A (https=) |
| PE (1) | PE20150863A1 (https=) |
| PH (1) | PH12014502857A1 (https=) |
| PL (1) | PL2864350T3 (https=) |
| PT (1) | PT2864350T (https=) |
| RS (1) | RS57347B1 (https=) |
| SG (1) | SG11201408491SA (https=) |
| SI (1) | SI2864350T1 (https=) |
| TR (1) | TR201808818T4 (https=) |
| TW (1) | TWI644920B (https=) |
| WO (1) | WO2013192130A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2841437T1 (sl) | 2012-04-26 | 2017-09-29 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| PE20150863A1 (es) * | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3082847A1 (en) | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN107108715A (zh) | 2014-10-24 | 2017-08-29 | 默沙东公司 | 胰高血糖素和glp‑1受体的共激动剂 |
| PE20171154A1 (es) | 2014-12-30 | 2017-08-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon con estabilidad mejorada |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| EP4523705A3 (en) | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| EP3479841A4 (en) | 2016-06-29 | 2020-03-04 | Hanmi Pharm. Co., Ltd. | GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物 |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| CN109836488B (zh) * | 2017-11-24 | 2022-08-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| SG11202010017SA (en) | 2018-04-10 | 2020-11-27 | Sanofi Aventis Deutschland | Method for cleavage of solid phase-bound peptides from the solid phase |
| KR102727918B1 (ko) | 2018-04-10 | 2024-11-11 | 사노피-아벤티스 도이칠란트 게엠베하 | 캡핑을 사용한 릭시세나티드 합성 |
| US11633459B2 (en) | 2018-05-04 | 2023-04-25 | Novo Nordisk A/S | GIP derivatives and uses thereof |
| UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| US11166910B2 (en) | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| CN114945589B (zh) * | 2020-02-24 | 2024-05-24 | 深圳市图微安创科技开发有限公司 | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 |
| CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| EP4185607A1 (en) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| CN114621327B (zh) * | 2020-12-10 | 2023-08-18 | 江苏中新医药有限公司 | GLP-1、GIP和Gcg多重受体激动蛋白质 |
| JP7573760B2 (ja) | 2020-12-23 | 2024-10-25 | 浙江道尓生物科技有限公司 | 長時間作用型グルカゴン誘導体 |
| US20240174728A1 (en) * | 2021-01-22 | 2024-05-30 | Shenzhen Turier Biotech Co., Ltd. | A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis |
| JP2024525843A (ja) * | 2021-07-16 | 2024-07-12 | ぺプ２タンゴ セラピューティクス インコーポレイテッド | マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
| JP7402574B1 (ja) * | 2023-03-15 | 2023-12-21 | 株式会社合同資源 | α－ヨード置換カルボン酸 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| AU2003279842A1 (en) | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US20080031957A1 (en) | 2006-05-15 | 2008-02-07 | Deluca Hector F | Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| CA2677932A1 (en) * | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2008130158A1 (en) | 2007-04-19 | 2008-10-30 | Dong-A Pharmaceutical. Co., Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| AR072160A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| EP2443146B1 (en) * | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| MX2012013001A (es) * | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
| EP2588126A4 (en) * | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| KR20140043793A (ko) * | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| RS56173B1 (sr) * | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| PE20150863A1 (es) * | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
-
2013
- 2013-06-18 PE PE2014002465A patent/PE20150863A1/es not_active Application Discontinuation
- 2013-06-18 SG SG11201408491SA patent/SG11201408491SA/en unknown
- 2013-06-18 AU AU2013277372A patent/AU2013277372B2/en not_active Ceased
- 2013-06-18 US US14/408,813 patent/US9868772B2/en not_active Expired - Fee Related
- 2013-06-18 RS RS20180728A patent/RS57347B1/sr unknown
- 2013-06-18 ES ES13731246.8T patent/ES2674946T3/es active Active
- 2013-06-18 MX MX2014015556A patent/MX356000B/es active IP Right Grant
- 2013-06-18 AR ARP130102143 patent/AR091478A1/es unknown
- 2013-06-18 WO PCT/US2013/046229 patent/WO2013192130A1/en not_active Ceased
- 2013-06-18 TW TW102121585A patent/TWI644920B/zh not_active IP Right Cessation
- 2013-06-18 JP JP2015518506A patent/JP6300239B2/ja not_active Expired - Fee Related
- 2013-06-18 MY MYPI2014003510A patent/MY185217A/en unknown
- 2013-06-18 DK DK13731246.8T patent/DK2864350T3/en active
- 2013-06-18 TR TR2018/08818T patent/TR201808818T4/tr unknown
- 2013-06-18 PL PL13731246T patent/PL2864350T3/pl unknown
- 2013-06-18 EP EP13731246.8A patent/EP2864350B1/en not_active Not-in-force
- 2013-06-18 CN CN201380043984.5A patent/CN104583233B/zh not_active Expired - Fee Related
- 2013-06-18 SI SI201331079T patent/SI2864350T1/en unknown
- 2013-06-18 KR KR20157001447A patent/KR20150039748A/ko not_active Abandoned
- 2013-06-18 HU HUE13731246A patent/HUE039267T2/hu unknown
- 2013-06-18 EA EA201590065A patent/EA029025B1/ru not_active IP Right Cessation
- 2013-06-18 PT PT137312468T patent/PT2864350T/pt unknown
- 2013-06-18 CA CA2877127A patent/CA2877127A1/en not_active Abandoned
- 2013-06-18 HR HRP20180936TT patent/HRP20180936T1/hr unknown
- 2013-06-18 BR BR112014031671A patent/BR112014031671A2/pt not_active Application Discontinuation
-
2014
- 2014-12-17 CL CL2014003421A patent/CL2014003421A1/es unknown
- 2014-12-21 IL IL236386A patent/IL236386B/en active IP Right Grant
- 2014-12-22 PH PH12014502857A patent/PH12014502857A1/en unknown
-
2015
- 2015-01-19 CR CR20150015A patent/CR20150015A/es not_active Application Discontinuation
- 2015-01-19 CO CO15009514A patent/CO7170125A2/es unknown
-
2017
- 2017-12-04 US US15/830,158 patent/US20180105569A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091478A1 (es) | Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa) | |
| PE20240686A1 (es) | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) | |
| EA201490982A1 (ru) | Аналоги глюкагона | |
| ECSP12012181A (es) | Nuevos péptidos y métodos para su preparación y uso | |
| ECSP12011593A (es) | Análogos de glucagón acilados | |
| PE20142405A1 (es) | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas | |
| CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
| CY1116917T1 (el) | Αναλογα οξυντομοντουλινης | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| NZ612297A (en) | Glucagon analogs exhibiting gip receptor activity | |
| AR092589A1 (es) | Analogos de glucagon | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| UY31596A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| CO6660484A2 (es) | Análogos de glucagón | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| CU24308B1 (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
| AR102406A1 (es) | Coagonistas de los receptores de glucagón y de glp-1 | |
| UY32781A (es) | Combinación de teriflunomida e interferón beta para el tratamiento de la esclerosis múltiple | |
| ECSP15009978A (es) | Análogos de glucagón |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |